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eight percent would consider the information when prescribing.
Seventy-ﬁve percent of the proﬁled physicians who responded
agreed that the proﬁles were informative and useful, and 67%
would consider the information in their prescribing decisions.
CONCLUSION: Providing antibiotic prescribing proﬁles for
physicians may inﬂuence prescribing patterns and maintain cost
in a managed care setting.
PIN28
MEDICOECONOMIC EVALUATION OF OUTPATIENT
MANAGEMENT OF INFANTILE BRONCHIOLITIS IN FRANCE
Vainchtock A1,Trichard M2, Chaufferin G2, Duru G3,
Nicoloyannis N4, Stagnara J5
1GYD Institut Groupe IMS Health, Lyon, France; 2BOIRON
Laboratories, Sainte-Foy-Lès-Lyon, France; 3Claude Bernard University,
Villeurbanne, France; 4Lyon 2 University, Bron, France; 5Paediatrician,
Lyon, France
OBJECTIVES: To compare—in terms of effectiveness and
costs—outpatient management of infantile bronchiolitis by
homeopathic GPs vs allopathic GPs vs paediatricians.
METHODS: A 6-month prospective, “real-world” study was
carried out by setting up 3 observatories with: homeopathic GPs,
allopathic GPs and paediatricians recruited by sample-drawing.
Patients aged between 3 and 24 months, consulting for ﬁrst bout
of acute bronchiolitis since birth, who had not yet received treat-
ment and who did not require immediate hospitalisation were
included. Effectiveness (number and duration of bouts, number
of complications, persistence of bronchial obstruction), direct
medical costs (from the French Health Insurance and societal
perspectives) and indirect costs (sick leaves) were assessed. The
statistical analysis was performed after matching patients to have
comparable patients. RESULTS: One hundred seventeen, 150
and 253 patients were respectively included by 38 homeopathic
GPs, 59 allopathic GPs and 95 paediatricians. At the end of the
study, there were: no signiﬁcant differences between the man-
agement by homeopathic GPs vs allopathic GPs on effectiveness
criteria; no signiﬁcant differences between the management by
homeopathic GPs vs paediatricians in terms of number of bouts,
persistence of bronchial obstruction but signiﬁcant shorter dura-
tion of bouts (4.4 vs 6.6 days) and less complications (0.20 vs
0.40 complication/patient) in the homeopathic group. In Health
Insurance perspective, the management by homeopathic GPs was
signiﬁcantly less expensive than the management by allopathic
GPs and paediatricians (116, 146, 217 €/patient respectively). In
the societal perspective, the management by homeopathic GPs
was signiﬁcantly less expensive than the management by paedi-
atricians (215 vs 361 €/patient) but equivalent to the manage-
ment by allopathic GPs. Homeopathic GPs prescribed equivalent
number of sick leaves to paediatricians but signiﬁcantly less than
allopathic GPs. CONCLUSION: These results could help public
policy makers and practitioners in providing new available data
concerning the outpatient management and cost of infantile
bronchiolitis, that is a public health concern in France.
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OBJECTIVES: Inﬂuenza infection is a major cause of illness,
morbidity and mortality throughout the world, mainly among
the elderly. Since vaccination has proven to be effective in the
reduction of all acute complications, deciding whether to imple-
ment a vaccination campaign, and which vaccine(s) to prescribe
is an important task. The aim of this work is to build a decision
model, which allows the decision-makers to evaluate the possi-
ble results under different scenarios, and to choose the decision
associated to the highest expected utility, in terms of incremen-
tal cost effectiveness ratio (ICER). METHODS: The analysis is
based on the Bayesian Networks. We developed a network that
combines information from an observational study conducted in
Pianiga (Italy) from a group of GPs (Family Medicine Group),
with literature and experts data. This information was used to
create a graph model, which encodes the set of conditional inde-
pendencies among the variables. The probabilities of the relevant
events (mortality and resources consumption) are calculated
using the network. A (dis)utility function, represented by direct
costs, is associated to the decision of implementing or not the
vaccination campaign with a given vaccine. The ICER is then
derived for several possible scenarios. RESULTS: The MF59
vaccine proves to be more cost-effective, as compared to both
the non-vaccination and the standard vaccine. This result is con-
sistent through several scenarios, built upon varying parameters
such as coverage and attack rates. In the basic scenario, obtained
by observed data, MF59 allows a saving of 16,444€ per death
averted, with respect to standard vaccine, and a saving of 
2718 € per death averted as compared to non vaccination. CON-
CLUSIONS: Using Bayesian Networks can help structure the
decision problem and allow for a direct multivariate stochastic
sensitivity analysis. The use this tool is in our opinion highly
valuable, yet not established, in health economics.
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OBJECTIVES: In this observational study, we analyzed the
minimum basic data sets (MBDS) together with the associated
medication costs, relating to stays from 11 hospitals. We focused
on Pneumonia stays considering the effect of antibiotic treatment
(SDT versus parenteral therapy), stay parameters and patient
characteristics on length of stay (LOS) and the resulting antibi-
otic national insurance cost. METHODS: Belgian hospitals 
register case mix data for admissions in MBDS: we extracted
anonymous medical data and prescribed drug cost data from
stays of 11 peripheral Flemish hospitals (during 2001). MBDS
contains ICD-9-CM codes and performed procedures as well as
other stay parameters (severity, risk of mortality, LOS), patient
characteristics (age, gender) and drug utilization data. Data were
stored in MS Access 2000 and analyzed in SPSSWIN 12.0. Stays
were considered independent; LOS and cost data were log trans-
formed to obtain homoscedasticity. RESULTS: The database
contained 302,704 patient stays: 6742 relate to pneumonia.
Pneumococcus pneumonia was reported in 472 stays (461
patients). Mean (SD) LOS was 16.3 (21.9) days; 89 % of the
admissions were unscheduled. Mortality was 8.1%. The 
frequency of antibiotic use was: Amoxicillin-Clavulanate 
63.9%, cephalosporins third generation 30,8%, quinolones
16.8%, cephalosporins second generation 15.7%, macrolides
15.7%, aminoglycosides 15.3%. In 48,9% one, in 25% two and
in 12% three AB-classes were administered. 37.7% SDT therapy
was used. LOS was unaffected by SDT but there was a signiﬁ-
cant effect (p < 0.001 Anova) of age, stay severity and the
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number of AB’s used. The mean (median) cost for parenteral AB-
therapy was 624.2 (275.3) Euro versus 504.4 (169.1) Euro for
SDT (p < 0.001 Anova). CONCLUSIONS: MBDS through ICD-
9-CM yields valuable information on “real life practice”. The
antibiotic-related cost in SDT is signiﬁcantly lower than full par-
enteral treatment; LOS corrected for age, gender, reason for
admission and departure was unaffected.
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OBJECTIVES: Fatigue is a common, distressing symptom in
HIV+ patients. This analysis evaluates whether substitution to
LPV/r, a generally well tolerated and efﬁcacious PI, affects fatigue
in HIV+ patients experiencing Grade 2 side effects (SE) attrib-
uted to their PI/NNRTI. METHODS: In the open-label PLATO
trial, patients experiencing Grade 2 PI/NNRTI-associated SE
were randomized (4:1) to immediate substitution (IS) of their
PI/NNRTI with LPV/r at baseline or deferred substitution (DS)
at Week 4 (Wk4). The MOS-HIV and ACTG Symptoms Distress
Module, with 2 additional items for nephrolithiasis (ASDM),
were administered at baseline, Wk4 and Wk8. Fatigue was 
measured by MOS-HIV fatigue-domain and ASDM fatigue/
bothersomeness-item. Sleep-disorder was measured by ASDM
sleep-disorder-item. The Center for Epidemiologic Studies-
Depression (CES-D) questionnaire was administered at baseline
and Wk8. RESULTS: Eight hundred twenty-seven patients 
previously on nelﬁnavir (n = 291), indinavir (n = 170), indi-
navir/ritonavir (n = 182), efavirenz (n = 136) or another
PI/NNRTI (n = 48) were analyzed (80% male, mean age 42yrs,
75% with baseline HIV RNA <50 copies/mL). At baseline, mean
MOS-HIV fatigue-domain score was 56.7, with 62.3% rating
fatigue as bothersome. Baseline fatigue scores were correlated 
(p < 0.05) with presence of depression (CES-D >= 16), sleep-
disorder, and years since HIV diagnosis. At Wk4, improved
fatigue scores were seen in IS vs. DS groups (MOS-HIV fatigue-
domain: +8.711 vs. +0.068, p < 0.001; ASDM fatigue/
bothersomeness-item: -0.486 vs. +0.074, p < 0.001), irrespective
of prior PI/NNRTI regimens. At Wk8, fatigue improvement
remained for IS group, while DS group began to improve.
Improved fatigue scores were associated (p < 0.05) with IS,
reduced prevalence of depression, and improved sleep-disorder
scores. Improvement in fatigue and IS were signiﬁcant predictors
of improved MOS-HIV physical health summary score at Wk4
(p < 0.05). CONCLUSIONS: Fatigue scores were improved fol-
lowing substitution with LPV/r, and were associated with
reduced prevalence of depression and improved sleep-disorder
scores. Improvement in fatigue was independent of prior
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OBJECTIVE: To examine antibiotic prescribing and outcomes
associated with acute sinusitis in managed care. METHODS:
We used the PharMetrics claims database for 8 managed care
organizations. Index claims were based on outpatient visits in
1999–2001 by individuals aged 45–64 with a primary diagnosis
of acute sinusitis who received an antibiotic within 7 days and
were continuously enrolled for 12 months prior to and 45 days
after the index event. Exclusion criteria: antibiotic prescription
or sinusitis diagnosis in prior 45 days, hospitalization in 
prior 30 days, or sinus complications in prior 12 months. Broad
spectrum antibiotics (BSA) were deﬁned as: azithromycin, 
clarithromycin, amoxicillin-clavulanate, second- and third-
generation cephalosporins, quinolones. Sinusitis history was 
categorized: chronic sinusitis (HxChr), acute but not chronic
sinusitis (HxAcu), no history (NoHx). Also, subjects with
asthma, chronic obstructive pulmonary disease (COPD), lower
and upper respiratory tract infection (LRTI, URTI),and rhinitis
in prior year were identiﬁed. Multivariate models adjusted for
age, sex, health plan, use of laboratory/diagnostic testing at
initial evaluation (surrogate for severity and practice variation).
RESULTS: Out of 64,277 cases, 66.1% female, met criteria. Res-
piratory history: 5.4% HxChr, 7.9% HxAcu, 4.5% asthma,
4.4% COPD, 24.6% URTI, 16.3% LRTI, 10.4% rhinitis. BSA
accounted for 45.5% of 1st-line prescriptions. BSA use increased
over 3 years (p < 0.0001): 43.8% (1999), 45.5% (2000), 49.2%
(2001). BSA use was highest for HxChr and asthma at 54.3%.
Overall, 22.4% received a 2nd prescription, highest among
HxChr, 31.7%. Mean charges were $134; highest for HxChr,
$158 and asthma, $152. In multivariate models, respiratory his-
tories were positively associated (p < 0.05) with BSA use, 2nd
prescriptions and charges. CONCLUSION: In treatment of acute
sinusitis in managed care, broad spectrum antibiotics are used
almost 50% of the time as initial therapy and use is rising. Res-
piratory history, especially chronic sinusitis or asthma, is associ-
ated with more BSA use, 2nd prescriptions, and charges.
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OBJECTIVES: This study was conducted to examine the uti-
lization patterns of medical services and prescription drugs in
patients with tinea capitis (TC). METHODS: This retrospective
cohort study identiﬁed TC patients using the MarketScan® data-
base during January 1, 1999–December 31, 2002. Patients were
selected if they had primary or secondary diagnosis of TC (ICD-
9 Code of 110) and had continuous health insurance and pre-
scription drug coverage. The identiﬁed patients were deﬁned as
newly diagnosed patients if they were not diagnosed with TC or
did not use any prescription drugs for TC treatment in the pre-
vious year. The frequency of medical services and the usage pat-
